Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Expression Pathology Inc.. (3/24/11). "Press Release: Expression Pathology Obtains Second U.S. Liquid Tissue Patent". Rockville, MD.

Region Region United States (USA)
Organisations Organisation Expression Pathology Inc. (EPI)
  Today OncoPlex Diagnostics (OncoPlexDx)
  Group OncoPlex Diagnostics (OncoPlexDx)
  Organisation 2 US Patent and Trademark Office (USPTO)
  Group United States (govt)
Product Product Liquid Tissue® technology (Expression Pathology)
Persons Person Eitner, Casey (Expression Pathology 200806 CEO)
  Person 2 Tunon, Peter (Expression Pathology 200501– VP Sales + Marketing)

Expression Pathology Inc. announced today that the U.S. Patent and Trademark Office issued patent number 7,906,301, MULTIPLEX METHOD FOR INCREASED PROTEOMIC COVERAGE FROM HISTOPATHOLOGICALLY PROCESSED BIOLOGICAL SAMPLES, TISSUES AND CELLS. The claims of the patent cover methods that increase the range of proteins and protein modifications which can be analyzed using the company’s patented Liquid Tissue® method.

Formalin fixation is the standard process used worldwide to preserve patient biopsies and surgical tissue, but it limits the ability to analyze proteins by advanced methodologies such as mass spectrometry. Liquid Tissue reagents and methods enable application of mass spectrometry for targeted quantitation of protein biomarkers.

“This new patent further strengthens our proprietary position with respect to methods for developing suitable target peptides for our Liquid Tissue-SRM assays”, says Casey Eitner, the company’s President and CEO. “Being able to digest the tissue with multiple enzymes, for example, opens the door to development of assays for target proteins and protein modifications that may not be amenable to analysis using standard SRM mass spectrometry methods”.

About Expression Pathology

Expression Pathology is a private biotech company advancing personalized medicine with assays that measure tumor signaling networks—at the functional protein level—in routine formalin-fixed paraffin-embedded (FFPE) patient tissue to individualize and improve cancer treatment decisions. The company is developing proprietary Liquid Tissue®-SRM companion diagnostic tests to support the development of drugs in clinical trials and to improve patient selection for targeted therapies already on the market. The company’s rapidly expanding menu of assays includes many of the key protein pathways for which targeted therapies are being developed, including EGFR, IGF-1R, SPARC, SRC, truncated (p95) HER2, HER3, and cMET.

The Liquid Tissue®-SRM assays make possible multiplexed protein quantification and Expression Pathology is exploiting its ability to accurately measure cancer pathway proteins and their activation, or phosphorylation states, and to do so in standard patient tissue and core needle biopsies, to develop more informative assays that can be widely adopted in medical practice.

For more information, please contact

Peter Tunon, VP Sales and Marketing
Expression Pathology Inc.
9620 Medical Center Drive
Rockville, MD 20850
Phone: 301.977.3654

Record changed: 2016-03-19


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for OncoPlex Diagnostics (OncoPlexDx)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [iito] Männer Ballett 650x80px

» top